NanoViricides (NNVC) News Today $2.24 +0.04 (+1.82%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 25 at 2:00 AM | americanbankingnews.comComparing NanoViricides (NYSE:NNVC) and Nuvectis Pharma (NASDAQ:NVCT)July 24 at 9:09 AM | proactiveinvestors.comNanoViricides spotlights lead drug candidate's potential as COVID therapyJuly 19, 2024 | americanbankingnews.comNanoViricides (NYSE:NNVC) Stock Rating Lowered by StockNews.comJuly 11, 2024 | proactiveinvestors.comNanoViricides discusses lead program and next stepsJuly 1, 2024 | proactiveinvestors.comNanoViricides hails broad potential of lead antiviral drug as it prepares to begin first Phase II trialJune 24, 2024 | proactiveinvestors.comNanoViricides hails the potential of NV-387 in combatting bird flu virus H5N1June 20, 2024 | proactiveinvestors.comNanoViricides says antiviral drug candidate shows promise in protecting lungs against Influenza AJune 11, 2024 | proactiveinvestors.comNanoViricides antiviral candidate 'may be first effective oral nanomedicine'June 4, 2024 | proactiveinvestors.comNanoViricides says lead asset exhibits desirable blood concentration profile for infrequent dosingMay 29, 2024 | finance.yahoo.comA First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and MoreMay 29, 2024 | proactiveinvestors.comNanoViricides CEO says lead asset NV-387 could be ‘holy grail' of antiviral medicinesMay 23, 2024 | proactiveinvestors.comNanoViricides taps Aagami to seek out licensing and partnership opportunitiesMay 23, 2024 | finance.yahoo.comNanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.May 21, 2024 | proactiveinvestors.comNanoViricides could generate ‘antiviral superdrug' for multiple diseases, analysts believeMay 20, 2024 | finanznachrichten.deNanoViricides, Inc.: Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential CureMay 20, 2024 | proactiveinvestors.comNanoViricides reports strong antiviral activity of NV-387 against RSVMay 19, 2024 | finance.yahoo.comNanoViricides, Inc. (NNVC) Stock Price, News, Quote & History - Yahoo FinanceMay 14, 2024 | proactiveinvestors.comNanoViricides unveils new data showing lead drug asset's strong activity against RSVMay 14, 2024 | finance.yahoo.comA Novel Broad-Spectrum Antiviral with Activity Against RSVMay 13, 2024 | proactiveinvestors.comNanoViricides CEO discusses NV-387's broad-spectrum antiviral potentialMay 10, 2024 | proactiveinvestors.comNanoViricides to showcase lead drug asset's progress at EF Hutton Annual Global ConferenceMay 10, 2024 | finanznachrichten.deNanoViricides, Inc.: NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York CityMay 8, 2024 | proactiveinvestors.comNanoViricides says lead asset shows antiviral activity against Smallpox and MpoxMay 8, 2024 | finanznachrichten.deNanoViricides, Inc.: A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/MpoxMay 8, 2024 | finance.yahoo.comNanoViricides, Inc. (NNVC)May 6, 2024 | ca.investing.comNanoViricides drug asset shows ‘superior antiviral effects’ against Influenza AMay 6, 2024 | msn.comNanoViricides, Outset Medical, EyePoint Pharmaceuticals among healthcare moversMay 6, 2024 | proactiveinvestors.comNanoViricides drug asset shows ‘superior antiviral effects' against Influenza AMay 6, 2024 | finanznachrichten.deNanoViricides, Inc.: A Novel Broad-Spectrum Antiviral with Activity Against Influenza AApril 30, 2024 | proactiveinvestors.comNanoViricides completes Phase 1 trial of lead asset NV-387February 26, 2024 | benzinga.comNanoviricides Stock (AMEX:NNVC) Earnings Dates and Earning CallsFebruary 15, 2024 | proactiveinvestors.comNanoViricides boosts liquidity measures and manufacturing capacity to support clinical trialsFebruary 15, 2024 | finance.yahoo.comNanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the HorizonFebruary 1, 2024 | benzinga.comA New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?February 1, 2024 | finance.yahoo.comClinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as AntibioticsJanuary 29, 2024 | proactiveinvestors.comNanoViricides successfully concludes first-in-human studyJanuary 29, 2024 | proactiveinvestors.comNanoViricides makes progress as it completes dosing in Phase 1a COVID studyJanuary 29, 2024 | finance.yahoo.comSafety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events FoundJanuary 8, 2024 | benzinga.comNanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024January 7, 2024 | morningstar.comNanoviricides Inc NNVCJanuary 4, 2024 | finanznachrichten.deNanoViricides, Inc.: NanoViricides to Present at the Biotech Showcase in San FransiscoDecember 1, 2023 | benzinga.comNanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387November 28, 2023 | proactiveinvestors.comNanoViricides completes Phase 1a/1b human clinical trial for its broad-spectrum antiviral drugNovember 28, 2023 | finance.yahoo.comThe Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricidesNovember 15, 2023 | proactiveinvestors.comNanoViricides continues to progress antiviral drug candidate...November 15, 2023 | finance.yahoo.comNanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional ApplicationsOctober 17, 2023 | proactiveinvestors.comNanoViricides updates investors on Phase 1a/1b trial of antiviral drug candidate for coronavirusOctober 16, 2023 | finance.yahoo.comNanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSVOctober 12, 2023 | finance.yahoo.comNanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ETSeptember 5, 2023 | finance.yahoo.comNNVC: NanoViricides Begins Clinical Trial of NV-CoV-2 Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Email Address “Generational Bull Run” Incoming (Ad)LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event. You can find out what they are by clicking here now. NNVC Media Mentions By Week NNVC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NNVC News Sentiment▼0.160.62▲Average Medical News Sentiment NNVC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NNVC Articles This Week▼21▲NNVC Articles Average Week Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vistagen Therapeutics News Anixa Biosciences News Aclaris Therapeutics News Sagimet Biosciences News InflaRx News Checkpoint Therapeutics News Cellectar Biosciences News Eton Pharmaceuticals News AEON Biopharma News Tiziana Life Sciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:NNVC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.